Sintilimab, as a PD-1 monoclonal antibody, can bind to PD-1 on the surface of T cells and block the binding between it and the ligand PD-L1, so that T cells and autoimmune reactions can play a normal role, thereby eliminating Tumor cell.5 This study evaluated the efficacy of sintilimumab combined with chemotherapy on advanced NSCLC by recording tumor markers and immune function before and after treatment. The gene discussed is CD274; the disease is neoplasm.